The use of nanopore analysis for discovering drugs which bind to α-synuclein for treatment of Parkinson's disease

European Journal of Medicinal Chemistry

Volumn 88, Issue , 2014, Pages 42-54

  Tavassoly, Omid ^a   Kakish, Joe ^a   Nokhrin, Sergiy ^a   Dmitriev, Oleg ^a   Lee, Jeremy S ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Caffeine; Curcumin; Induced folding; Intrinsically disordered protein; Nanopore analysis; Nicotine; Parkinson's disease; Synuclein

Indexed keywords

3 O METHYLDOPAMINE; ALPHA SYNUCLEIN; ANABASINE; CAFFEINE; COTININE; CURCUMIN; NICOTINE; ALPHA-SYNUCLEIN; BIOLOGICAL PRODUCTS;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; DRUG PROTEIN BINDING; ISOTHERMAL TITRATION CALORIMETRY; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PROTEIN FOLDING; STEREOISOMERISM; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BINDING SITES; CALORIMETRY; CHEMISTRY; DRUG DISCOVERY; HUMANS; ISOLATION AND PURIFICATION; METABOLISM; METHODS; MOLECULAR CONFORMATION; NANOPORES; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP;

ALPHA-SYNUCLEIN; BINDING SITES; BIOLOGICAL PRODUCTS; CAFFEINE; CALORIMETRY; DRUG DISCOVERY; HUMANS; MOLECULAR CONFORMATION; NANOPORES; NICOTINE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PARKINSON DISEASE; PROTEIN FOLDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84911491507     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.07.090     Document Type: Article

References (104)

1. N. Gregersen, P. Bross, S. Vang, J.H. Christensen, Protein misfolding and human disease, Annu. Rev. Genomics Hum. Genet. 7 (2006) 103-124.
2. E. Herczenik, M.F.B.G. Gebbink, Molecular and cellular aspects of protein misfolding and disease, FASEB J. 22 (2008) 2115-2133.
3. P.J. Muchowski, Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones, Neuron 35 (2002) 9-12.
4. C. Soto, Unfolding the role of protein misfolding in neurodegenerative diseases, Nat. Rev. Neurosci. 4 (2003) 49-60.
5. C. Soto, L.D. Estrada, Protein misfolding and neurodegeneration, Arch. Neurol. 65 (2008) 184-189.
6. L. Breydo, J.W.Wu, V.N. Uversky, Alpha-synuclein misfolding and Parkinson's disease, Biochim. Biophys. Acta 1822 (2012) 261-285.
7. G. Forloni, L. Terreni, I. Bertani, S. Fogliarino, R. Invernizzi, A. Assini, G. Ribizzi, A. Negro, E. Calabrese, M.A. Volonte, C. Mariani, M. Franceschi, M. Tabaton, A. Bertoli, Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms, Neurobiol. Aging 23 (2002) 957-976.
8. A.L. Horwich, J.S. Weissman, Deadly conformationsdprotein misfolding in prion disease, Cell 89 (1997) 499-510.
9. R.A. Moore, L.M. Taubner, S.A. Priola, Prion protein misfolding and disease, Curr. Opin. Struct. Biol. 19 (2009) 14-22.
10. R. Roychaudhuri, M. Yang, M.M. Hoshi, D.B. Teplow, Amyloid b-protein assembly and Alzheimer disease, J. Biol. Chem. 284 (2009) 4749-4753.
11. C.A. Ross, M.A. Poirier, Protein aggregation and neurodegenerative disease, Nat. Med. 10 (2004) S10-S17.
12. A. Horwich, Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions, J. Clin. Investig. 110 (2002) 1221-1232.
13. I. Moreno-Gonzalez, C. Soto, Misfolded protein aggregates: mechanisms, structures and potential for disease transmission, Semin. Cell Dev. Biol. 22 (2011) 482-487.
14. C. Weissmann, M. Enari, P.-C. Klöhn, D. Rossi, E. Flechsig, Transmission of prions, J. Infect. Dis. 186 (2002) S157-S165.
15. V. Beringue, L. Herzog, E. Jaumain, F. Reine, P. Sibille, A. Le Dur, J.L. Vilotte, H. Laude, Facilitated cross-species transmission of prions in extraneural tissue, Science 335 (2012) 472-475.
16. C.J. Sigurdson, K.P. Nilsson, S. Hornemann, G. Manco, N. Fernandez-Borges, P. Schwarz, J. Castilla, K. Wuthrich, A. Aguzzi, A molecular switch controls interspecies prion disease transmission in mice, J. Clin. Investig. 120 (2010) 2590-2599.
17. J.L. Guo, V.M.Y. Lee, Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases, Nat. Med. 20 (2014) 130-138.
18. M. Jucker, L.C. Walker, Self-propagation of pathogenic protein aggregates in neurodegenerative diseases, Nature 501 (2013) 45-51.
19. M. Goedert, F. Clavaguera, M. Tolnay, The propagation of prion-like protein inclusions in neurodegenerative diseases, Trends Neurosci. 33 (2010) 317-325.
20. K.C. Luk, C. Song, P. O'Brien, A. Stieber, J.R. Branch, K.R. Brunden, J.Q. Trojanowski, V.M.-Y. Lee, Exogenous a-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells, Proc. Natl. Acad. Sci. 106 (2009) 20051-20056.
21. Laura A. Volpicelli-Daley, Kelvin C. Luk, Tapan P. Patel, Selcuk A. Tanik, Dawn M. Riddle, A. Stieber, David F. Meaney, John Q. Trojanowski, Virginia M.Y. Lee, Exogenous a-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death, Neuron 72 (2011) 57-71.
22. J. Domert, S.B. Rao, L. Agholme, A.C. Brorsson, J. Marcusson, M. Hallbeck, S. Nath, Spreading of amyloid-beta peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance, Neurobiol. Dis. 65 (2014) 82-92.
23. K.C. Luk, V. Kehm, J. Carroll, B. Zhang, P. O'Brien, J.Q. Trojanowski, V.M.-Y. Lee, Pathological a-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice, Science 338 (2012) 949-953.
24. W.W. Smith, H. Jiang, Z. Pei, Y. Tanaka, H. Morita, A. Sawa, V.L. Dawson, T.M. Dawson, C.A. Ross, Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity, Hum. Mol. Genet. 14 (2005) 3801-3811.
25. G. Mercado, P. Valdes, C. Hetz, An ERcentric view of Parkinson's disease, Trends Mol. Med. 19 (2013) 165-175.
26. A. Bellucci, L. Navarria, M. Zaltieri, E. Falarti, S. Bodei, S. Sigala, L. Battistin, M. Spillantini, C. Missale, P. Spano, Induction of the unfolded protein response by a-synuclein in experimental models of Parkinson's disease, J. Neurochem. 116 (2011) 588-605.
27. M.S. Gorbatyuk, A. Shabashvili, W. Chen, C. Meyers, L.F. Sullivan, M. Salganik, J.H. Lin, A.S. Lewin, N. Muzyczka, O.S. Gorbatyuk, Glucose regulated protein 78 diminishes alpha-synuclein neurotoxicity in a rat model of Parkinson disease, Mol. Ther. 20 (2012) 1327-1337.
28. A.A. Cooper, A.D. Gitler, A. Cashikar, C.M. Haynes, K.J. Hill, B. Bhullar, K. Liu, K. Xu, K.E. Strathearn, F. Liu, S. Cao, K.A. Caldwell, G.A. Caldwell, G. Marsischky, R.D. Kolodner, J. Labaer, J.C. Rochet, N.M. Bonini, S. Lindquist, Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models, Science 313 (2006) 324-328.
29. D.E. Spratt, R. Julio Martinez-Torres, Y.J. Noh, P. Mercier, N. Manczyk, K.R. Barber, J.D. Aguirre, L. Burchell, A. Purkiss, H. Walden, G.S. Shaw, A molecular explanation for the recessive nature of parkin-linked Parkinson's disease, Nat. Commun. 4 (2013).
30. K.E. Morrison, Parkin mutations and early onset parkinsonism, Brain 126 (2003) 1250-1251.
31. B.E. Riley, J.C. Lougheed, K. Callaway, M. Velasquez, E. Brecht, L. Nguyen, T. Shaler, D. Walker, Y. Yang, K. Regnstrom, L. Diep, Z. Zhang, S. Chiou, M. Bova, D.R. Artis, N. Yao, J. Baker, T. Yednock, J.A. Johnston, Structure and function of Parkin -3 ubiquitin ligase reveals aspects of RING and HECT ligases, Nat. Commun. 4 (2013).
32. J.-F. Trempe, V. Sauvé, K. Grenier, M. Seirafi, M.Y. Tang, M. Ménade, S. Al- Abdul-Wahid, J. Krett, K. Wong, G. Kozlov, B. Nagar, E.A. Fon, K. Gehring, Structure of parkin reveals mechanisms for ubiquitin ligase activation, Science 340 (2013) 1451-1455.
33. Y.C. Tsai, P.S. Fishman, N.V. Thakor, G.A. Oyler, Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function, J. Biol. Chem. 278 (2003) 22044-22055.
34. A. Recchia, P. Debetto, A. Negro, D. Guidolin, S.D. Skaper, P. Giusti, a-Synuclein and Parkinson's disease, FASEB J. 18 (2004) 617-626.
35. H.A. Lashuel, C.R. Overk, A. Oueslati, E. Masliah, The many faces of [alpha]- synuclein: from structure and toxicity to therapeutic target, Nat. Rev. Neurosci. 14 (2013) 38-48.
36. M. Goedert, Alpha-synuclein and neurodegenerative diseases, Nat. Rev. Neurosci. 2 (2001) 492-501.
37. K. Nishioka, S. Hayashi, M.J. Farrer, A.B. Singleton, H. Yoshino, H. Imai, T. Kitami, K. Sato, R. Kuroda, H. Tomiyama, K. Mizoguchi, M. Murata, T. Toda, I. Imoto, J. Inazawa, Y. Mizuno, N. Hattori, Clinical heterogeneity of a-synuclein gene duplication in Parkinson's disease, Ann. Neurol. 59 (2006) 298-309.
38. P. Ibanez, A.M. Bonnet, B. Debarges, E. Lohmann, F. Tison, P. Pollak, Y. Agid, A. Durr, A. Brice, Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease, Lancet 364 (2004) 1169-1171.
39. T.-B. Ahn, S.Y. Kim, J.Y. Kim, S.-S. Park, D.S. Lee, H.J. Min, Y.K. Kim, S.E. Kim, J.- M. Kim, H.-J. Kim, J. Cho, B.S. Jeon, α-Synuclein gene duplication is present in sporadic Parkinson disease, Neurology 70 (2008) 43-49.
40. N.-Y. Zhang, Z. Tang, C.-W. Liu, α-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation, J. Biol. Chem. 283 (2008) 20288-20298.
41. E. Emmanouilidou, L. Stefanis, K. Vekrellis, Cell-produced a-synuclein oligomers are targeted to, and impair, the 26S proteasome, Neurobiol. Aging 31 (2010) 953-968.
42. M. Masuda, N. Suzuki, S. Taniguchi, T. Oikawa, T. Nonaka, T. Iwatsubo, S. Hisanaga, M. Goedert, M. Hasegawa, Small molecule inhibitors of alphasynuclein filament assembly, Biochemistry 45 (2006) 6085-6094.
43. K. Ono, M. Yamada, Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro, J. Neurochem. 97 (2006) 105-115.
44. N. Pandey, J. Strider, W.C. Nolan, S.X. Yan, J.E. Galvin, Curcumin inhibits aggregation of alpha-synuclein, Acta Neuropathol. 115 (2008) 479-489.
45. X. Meng, L.A. Munishkina, A.L. Fink, V.N. Uversky, Effects of various flavonoids on the alpha-synuclein fibrillation process, Parkinsons Dis. 2010 (2010) 650794.
46. S. Di Giovanni, S. Eleuteri, K.E. Paleologou, G. Yin, M. Zweckstetter, P.A. Carrupt, H.A. Lashuel, Entacapone and tolcapone, two catechol Omethyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity, J. Biol. Chem. 285 (2010) 14941-14954.
47. C.A. Braga, C. Follmer, F.L. Palhano, E. Khattar, M.S. Freitas, L. Romao, S. Di Giovanni, H.A. Lashuel, J.L. Silva, D. Foguel, The anti-Parkinsonian drug selegiline delays the nucleation phase of alpha-synuclein aggregation leading to the formation of nontoxic species, J. Mol. Biol. 405 (2011) 254-273.
48. K. Ono, M. Hirohata, M. Yamada, Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro, J. Neurosci. Res. 85 (2007) 1547-1557.
49. Y.S. Kim, D. Lim, J.Y. Kim, S.J. Kang, Y.H. Kim, H. Im, beta-sheet-breaking peptides inhibit the fibrillation of human alpha-synuclein, Biochem. Biophys. Res. Commun. 387 (2009) 682-687.
50. C. Soto, E.M. Sigurdsson, L.Morelli, R.A. Kumar, E.M. Castano, B. Frangione, Betasheet breaker peptides inhibit fibrillogenesis ina rat brainmodel of amyloidosis: implications for Alzheimer's therapy, Nat. Med. 4 (1998) 822-826.
51. M.H. Viet, S.T. Ngo, N.S. Lam, M.S. Li, Inhibition of aggregation of amyloid peptides by beta-sheet breaker peptides and their binding affinity, J. Phys. Chem. B 115 (2011) 7433-7446.
52. M.G. Chini, M. Scrima, A.M. D'Ursi, G. Bifulco, Fibril aggregation inhibitory activity of the beta-sheet breaker peptides: a molecular docking approach, J. Pept. Sci. 15 (2009) 229-234.
53. S.L. Leong, R. Cappai, K.J. Barnham, C.L. Pham, Modulation of alpha-synuclein aggregation by dopamine: a review, Neurochem. Res. 34 (2009) 1838-1846.
54. P.N. Jethva, J.R. Kardani, I. Roy, Modulation of alpha-synuclein aggregation by dopamine in the presence of MPTP and its metabolite, FEBS J. 278 (2011) 1688-1698.
55. D. Latawiec, F. Herrera, A. Bek, V. Losasso, M. Candotti, F. Benetti, E. Carlino, A. Kranjc, M. Lazzarino, S. Gustincich, P. Carloni, G. Legname, Modulation of alpha-synuclein aggregation by dopamine analogs, PLoS One 5 (2010) e9234.
56. J. Li, M. Zhu, A.B. Manning-Bog, D.A. Di Monte, A.L. Fink, Dopamine and Ldopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease, FASEB J. 18 (2004) 962-964.
57. M. Bisaglia, L. Tosatto, F. Munari, I. Tessari, P.P. de Laureto, S. Mammi, L. Bubacco, Dopamine quinones interact with alpha-synuclein to form unstructured adducts, Biochem. Biophys. Res. Commun. 394 (2010) 424-428.
58. N.-E. Andén, K. Fuxe, B. Hamberoer, T. Hökfelt, A quantitative study on the nigro-neostriatal dopamine neuron system in the rat, Acta Physiol. Scand. 67 (1966) 306-312.
59. J.P.E. Spencer, A. Jenner, J. Butler, O.I. Aruoma, D.T. Dexter, P. Jenner, B. Halliwell, Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease, Free Radic. Res. 24 (1996) 95-105.
60. P. Huot, M. Levesque, A. Parent, The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea, Brain 130 (2007) 222-232.
61. G. Drui, S. Carnicella, C. Carcenac, M. Favier, A. Bertrand, S. Boulet, M. Savasta, Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson/'s disease, Mol. Psychiatry 19 (2014) 358-367.
62. A.H. Schapira, P. Jenner, Etiology and pathogenesis of Parkinson's disease, Mov. Disord. 26 (2011) 1049-1055.
63. R.C. Callaghan, J.K. Cunningham, G. Sajeev, S.J. Kish, Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders, Mov. Disord. 25 (2010) 2333-2339.
64. R.C. Callaghan, J.K. Cunningham, J. Sykes, S.J. Kish, Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs, Drug Alcohol Depend. 120 (2012) 35-40.
65. C.M. Tanner, F. Kamel, G.W. Ross, J.A. Hoppin, S.M. Goldman, M. Korell, C. Marras, G.S. Bhudhikanok, M. Kasten, A.R. Chade, K. Comyns, M.B. Richards, C. Meng, B. Priestley, H.H. Fernandez, F. Cambi, D.M. Umbach, A. Blair, D.P. Sandler, J.W. Langston, Rotenone, paraquat, and Parkinson's disease, Environ. Health Perspect. 119 (2011) 866-872.
66. O. Tavassoly, J.S. Lee, Methamphetamine binds to alpha-synuclein and causes a conformational change which can be detected by nanopore analysis, FEBS Lett. 586 (2012) 3222-3228.
67. G. Ross, R.D. Abbott, H. Petrovitch, et al., Association of coffee and caffeine intake with the risk of Parkinson disease, J. Am. Med. Assoc. 283 (2000) 2674-2679.
68. R.B. Postuma, A.E. Lang, R.P. Munhoz, K. Charland, A. Pelletier, M. Moscovich, L. Filla, D. Zanatta, S.R. Romenets, R. Altman, R. Chuang, B. Shah, Caffeine for treatment of Parkinson disease: a randomized controlled trial, Neurology 79 (2012) 651-658.
69. R.D. Prediger, Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms, J. Alzheimers Dis. 20 (Suppl. 1) (2010) S205-S220.
70. G.W. Ross, H. Petrovitch, Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease, Drugs Aging 18 (2001) 797-806.
71. M. Quik, X.A. Perez, T. Bordia, Nicotine as a potential neuroprotective agent for Parkinson's disease, Mov. Disord. 27 (2012) 947-957.
72. M. Quik, Smoking, nicotine and Parkinson's disease, Trends Neurosci. 27 (2004) 561-568.
73. R.B. Mythri, M.M. Bharath, Curcumin: a potential neuroprotective agent in Parkinson's disease, Curr. Pharm. Des. 18 (2012) 91-99.
74. J. Pan, H. Li, J.F. Ma, Y.Y. Tan, Q. Xiao, J.Q. Ding, S.D. Chen, Curcumin inhibition of JNKs prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease through suppressing mitochondria dysfunction, Transl. Neurodegener. 1 (2012) 16.
75. G. Wang, L. Wang, Y. Han, S. Zhou, X. Guan, Nanopore detection of copper ions using a polyhistidine probe, Biosens. Bioelectron. 53 (2014) 453-458.
76. D.J. Niedzwiecki, R. Iyer, P.N. Borer, L. Movileanu, Sampling a biomarker of the human immunodeficiency virus across a synthetic nanopore, ACS Nano 7 (2013) 3341-3350.
77. A. Asandei, S. Iftemi, L. Mereuta, I. Schiopu, T. Luchian, Probing of various physiologically relevant metals: amyloid-b peptide interactions with a lipid membrane-immobilized protein nanopore, J. Membr. Biol. 247 (2014) 523-530.
78. A. Asandei, I. Schiopu, S. Iftemi, L. Mereuta, T. Luchian, Investigation of Cu2+ binding to human and rat amyloid fragments Ab (1-16) with a protein nanopore, Langmuir 29 (2013) 15634-15642.
79. C. Madampage, O. Tavassoly, C. Christensen, M. Kumari, J.S. Lee, Nanopore analysis: an emerging technique for studying the folding and misfolding of proteins, Prion 6 (2012).
80. O. Tavassoly, S. Nokhrin, O.Y. Dmitriev, J.S. Lee, Cu(II) and dopamine bind to alpha-Synuclein and cause large conformational changes, FEBS J. 12 (2014) 2738-2753.
81. C. Christensen, C. Baran, B. Krasniqi, R.I. Stefureac, S. Nokhrin, J.S. Lee, Effect of charge, topology and orientation of the electric field on the interaction of peptides with the alpha-hemolysin pore, J. Pept. Sci. 17 (2011) 726-734.
82. H. Meng, D. Detillieux, C. Baran, B. Krasniqi, C. Christensen, C. Madampage, R.I. Stefureac, J.S. Lee, Nanopore analysis of tethered peptides, J. Pept. Sci. 16 (2010) 701-708.
83. R. Stefureac, Y.T. Long, H.B. Kraatz, P. Howard, J.S. Lee, Transport of alphahelical peptides through alpha-hemolysin and aerolysin pores, Biochemistry 45 (2006) 9172-9179.
84. R. Stefureac, L. Waldner, P. Howard, J.S. Lee, Nanopore analysis of a small 86- residue protein, Small 4 (2008) 59-63.
85. R.I. Stefureac, J.S. Lee, Nanopore analysis of the folding of zinc fingers, Small 4 (2008) 1646-1650.
86. R.I. Stefureac, C.A. Madampage, O. Andrievskaia, J.S. Lee, Nanopore analysis of the interaction of metal ions with prion proteins and peptides, Biochem. Cell Biol. 88 (2010) 347-358.
87. C.A. Madampage, O. Andrievskaia, J.S. Lee, Nanopore detection of antibody prion interactions, Anal. Biochem. 396 (2010) 36-41.
88. B. Krasniqi, J.S. Lee, RNase A does not translocate the alpha-hemolysin pore, PLoS One 9 (2014) e88004.
89. J.S. Schneider, M. Giardiniere, P. Morain, Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys, Neuropsychopharmacology 26 (2002) 176-182.
90. P. Morain, P. Lestage, G. De Nanteuil, R. Jochemsen, J.L. Robin, D. Guez, P.A. Boyer, S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies, CNS Drug Rev. 8 (2002) 31-52.
91. P. Morain, P.H. Boeijinga, A. Demazieres, G. De Nanteuil, R. Luthringer, Psychotropic profile of S17092, a prolylendopeptidaseinhibitor,usingquantitativeEEG in young healthy volunteers, Neuropsychobiology 55 (2007) 176-183.
92. G. Oepen, K. Eisele, U. Thoden, W. Birg, Piracetam improves visuomotor and cognitive deficits in early Parkinsonism e a pilot study, Pharmacopsychiatry 18 (1985) 343-346.
93. P. Brown, M.J. Steiger, P.D. Thompson, J.C. Rothwell, B.L. Day, M. Salama, T. Waegemans, C.D. Marsden, Effectiveness of piracetam in cortical myoclonus, Mov. Disord. 8 (1993) 63-68.
94. P. Genton, R. Guerrini, C. Remy, Piracetam in the treatment of cortical myoclonus, Pharmacopsychiatry 32 (1999) 49-53.
95. P. Morain, J.L. Robin, G. De Nanteuil, R. Jochemsen, V. Heidet, D. Guez, Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study, Br. J. Clin. Pharmacol. 50 (2000) 350-359.
96. D.-P. Hong, A.L. Fink, V.N. Uversky, Smoking and Parkinson's disease: does nicotine affect a-synuclein fibrillation? Biochim. Biophys. Acta 1794 (2009) 282-290.
97. T.-F. Jiang, Y.-J. Zhang, H.-Y. Zhou, H.-M. Wang, L.-P. Tian, J. Liu, J.-Q. Ding, S.- D. Chen, Curcumin ameliorates the neurodegenerative pathology in A53T asynuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy, J. Neuroimmune Pharmacol. 8 (2013) 356-369.
98. B. Ahmad, L.J. Lapidus, Curcumin prevents aggregation in a-synuclein by increasing reconfiguration rate, J. Biol. Chem. 287 (2012) 9193-9199.
99. K. Ono, M. Hirohata, M. Yamada, Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: Implications for the prevention and therapeutics of Lewy body diseases, Exp. Neurol. 205 (2007) 414-424.
100. W. Hoyer, D. Cherny, V. Subramaniam, T.M. Jovin, Impact of the acidic Cterminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro, Biochemistry 43 (2004) 16233-16242.
101. V.N. Uversky, J. Li, A.L. Fink, Evidence for a partially folded intermediate in alpha-synuclein fibril formation, J. Biol. Chem. 276 (2001) 10737-10744.
102. P.J. Hajduk, J. Greer, A decade of fragment-based drug design: strategic advances and lessons learned, Nat. Rev. Drug Discov. 6 (2007) 211-219.
103. F. Delaglio, S. Grzesiek, G. Vuister, G. Zhu, J. Pfeifer, A. Bax, NMRPipe: a multidimensional spectral processing system based on UNIX pipes, J. Biomol. NMR 6 (1995) 277-293.
104. B. Johnson, R. Blevins, NMR view: a computer program for the visualization and analysis of NMR data, J. Biomol. NMR 4 (1994) 603-614.